logo

Ultragenyx Pharmaceutical Inc (RARE)



Trade RARE now with
  Date
  Headline
5/6/2020 4:59:17 PM Ultragenyx Pharma Q1 Loss/share $2.05 Vs. Loss $1.82 Year Ago
3/16/2020 8:42:53 AM GeneTx And Ultragenyx Report First Patient Dosed In Phase 1/2 Clinical Trial Of GTX-102
2/13/2020 4:05:02 PM Ultragenyx Pharma Q4 Loss/share $1.62 Vs. Loss $1.73 Year Ago
12/18/2019 8:38:25 AM Ultragenyx Reports Sale Of Future European Royalties On Crysvita For $320 Mln To Royalty Pharma
10/14/2019 8:45:11 AM Ultragenyx Says FDA Accepted For Review NDA For UX007
9/3/2019 8:35:03 AM GeneTx And Ultragenyx: FDA Grant Orphan Drug Designation And Rare Pediatric Disease Designation To GTX-102
8/1/2019 8:37:40 AM Ultragenyx Submits NDA For UX007 For Long-Chain Fatty Acid Oxidation Disorders
5/7/2019 9:21:54 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) FY19 Rev. Estimate To 95.1 M From 116.8 M
5/7/2019 9:21:42 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q4 19 Rev. Estimate To 30.4 M From 37.3 M
5/7/2019 9:21:31 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q3 19 Rev. Estimate To 25.3 M From 31.2 M
5/7/2019 8:53:51 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q2 19 Rev. Estimate To 21.3 M From 26.3 M
5/7/2019 8:53:03 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) FY19 Estimate To -7.07 From -6.37
5/7/2019 8:52:43 AM Wedbush Is Cutting Ultragenyx Pharmaceutical Inc (RARE) Q4 19 Estimate To -1.73 From -1.41
5/7/2019 8:52:17 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q3 19 Estimate To -1.75 From -1.61
5/7/2019 8:50:52 AM Wedbush Is Lowering Ultragenyx Pharmaceutical Inc (RARE) Q2 19 Estimate To -1.76 From -1.65